Suppr超能文献

理解鳞状细胞癌的免疫微环境。

Understanding the squamous cell carcinoma immune microenvironment.

机构信息

Section of Dermatologic Surgery, Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York, NY, United States.

出版信息

Front Immunol. 2023 Jan 30;14:1084873. doi: 10.3389/fimmu.2023.1084873. eCollection 2023.

Abstract

Primary cutaneous squamous cell carcinoma (cSCC) is the second most common human cancer with a rising incidence of about 1.8 million in the United States annually. Primary cSCC is usually curable by surgery; however, in some cases, cSCC eventuates in nodal metastasis and death from disease specific death. cSCC results in up to 15,000 deaths each year in the United States. Until recently, non-surgical options for treatment of locally advanced or metastatic cSCC were largely ineffective. With the advent of checkpoint inhibitor immunotherapy, including cemiplimab and pembrolizumab, response rates climbed to 50%, representing a vast improvement over chemotherapeutic agents used previously. Herein, we discuss the phenotype and function of SCC associated Langerhans cells, dendritic cells, macrophages, myeloid derived suppressor cells and T cells as well as SCC-associated lymphatics and blood vessels. Possible role(s) of SCC-associated cytokines in progression and invasion are reviewed. We also discuss the SCC immune microenvironment in the context of currently available and pipeline therapeutics.

摘要

原发性皮肤鳞状细胞癌(cSCC)是第二常见的人类癌症,美国每年约有 180 万人的发病率呈上升趋势。原发性 cSCC 通常可通过手术治愈;然而,在某些情况下,cSCC 会导致淋巴结转移和疾病特异性死亡。在美国,每年有多达 15000 人死于 cSCC。直到最近,局部晚期或转移性 cSCC 的非手术治疗选择在很大程度上效果不佳。随着检查点抑制剂免疫疗法的出现,包括 cemiplimab 和 pembrolizumab,反应率攀升至 50%,与之前使用的化疗药物相比有了显著的改善。在此,我们讨论了与 SCC 相关的朗格汉斯细胞、树突状细胞、巨噬细胞、髓系来源的抑制细胞和 T 细胞以及与 SCC 相关的淋巴管和血管的表型和功能。还讨论了 SCC 相关细胞因子在进展和侵袭中的可能作用。我们还讨论了 SCC 免疫微环境在现有治疗药物和药物研发中的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c9/9922717/8ab95a4ee85d/fimmu-14-1084873-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验